A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

NCT00109265 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Erlotinib HCl (OSI-774)

Sponsor

Genentech, Inc.